Author/Authors :
deVere White، نويسنده , , Ralph W. and Deitch، نويسنده , , Arline D. and Tesluk، نويسنده , , Henry and Blumensteinj، نويسنده , , Brent and Lowe، نويسنده , , Bruce A. and Sagalowsky، نويسنده , , Arthur I. and Smith Jr.، نويسنده , , Joseph A. and Schellhammer، نويسنده , , Paul F. and Stanisic، نويسنده , , Thomas H. and Grossman، نويسنده , , H.Barton and Messing، نويسنده , , Edward and Crissman، نويسنده , , John D. and Crawford، نويسنده , , E.David، نويسنده ,
Abstract :
While 80% of transitional cell carcinomas (TCC) present as TaTl lesions, they account for only 15% of deaths caused by TCC. We have evaluated the ability of DNA ploidy analysis to predict outcome in 228 patients with TaTl TCC. All patients were judged to be at increased risk for tumor recurrence due to having two occurrences of Stage TI tumor within 56 weeks, or three or more tumors presenting simultaneously within 16 weeks of registration. Concurrent carcinoma in situ was acceptable. All patients were treated with either bacillus Calmette Guerin (BCG) immunotherapy or mitomycin-C (MMC) intravesical chemotherapy. Patients with nondiploid tumors had higher hazard rates for both tumor progression and death (p = 0.007 and p = 0.016, respectively); however, the prognostic information of DNA ploidy was not additive to tumor grade.
